ATE277629T1 - Morphogenische behandlung des chronischen nierenversagens - Google Patents

Morphogenische behandlung des chronischen nierenversagens

Info

Publication number
ATE277629T1
ATE277629T1 AT97922726T AT97922726T ATE277629T1 AT E277629 T1 ATE277629 T1 AT E277629T1 AT 97922726 T AT97922726 T AT 97922726T AT 97922726 T AT97922726 T AT 97922726T AT E277629 T1 ATE277629 T1 AT E277629T1
Authority
AT
Austria
Prior art keywords
treatment
chronic kidney
kidney failure
risk
morphogenic
Prior art date
Application number
AT97922726T
Other languages
English (en)
Inventor
Kuber T Sampath
Charles M Cohen
Slobodan Vukicevic
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of ATE277629T1 publication Critical patent/ATE277629T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT97922726T 1996-05-06 1997-05-06 Morphogenische behandlung des chronischen nierenversagens ATE277629T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/643,321 US6498142B1 (en) 1996-05-06 1996-05-06 Morphogen treatment for chronic renal failure
PCT/US1997/007816 WO1997041881A1 (en) 1996-05-06 1997-05-06 Morphogen treatment for chronic renal failure

Publications (1)

Publication Number Publication Date
ATE277629T1 true ATE277629T1 (de) 2004-10-15

Family

ID=24580305

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97922726T ATE277629T1 (de) 1996-05-06 1997-05-06 Morphogenische behandlung des chronischen nierenversagens
AT97923567T ATE245997T1 (de) 1996-05-06 1997-05-06 Therapien des chronischen nierenversagens

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97923567T ATE245997T1 (de) 1996-05-06 1997-05-06 Therapien des chronischen nierenversagens

Country Status (11)

Country Link
US (5) US6498142B1 (de)
EP (2) EP0910400B1 (de)
JP (4) JP2000510835A (de)
AT (2) ATE277629T1 (de)
AU (2) AU2933997A (de)
CA (2) CA2254954C (de)
DE (2) DE69730966T2 (de)
DK (2) DK0914146T3 (de)
ES (2) ES2203803T3 (de)
PT (2) PT910400E (de)
WO (2) WO1997041881A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
DE69826854T2 (de) * 1997-05-05 2006-02-02 Curis, Inc., Cambridge Therapien zur behandlung von akutem nierenversagen
WO1998050061A1 (en) * 1997-05-07 1998-11-12 Biogen, Inc. Novel therapies for cystic kidney disease
DE69714035T2 (de) 1997-08-14 2003-03-06 Sulzer Innotec Ag Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren
US6203788B1 (en) * 1997-09-29 2001-03-20 Adherex Inc. Compounds and methods for regulating cell adhesion
EP1037910A2 (de) * 1997-12-04 2000-09-27 Curis, Inc. Nachschutz der glatte muskulatur durch morphogenetische protein
NZ528341A (en) * 1998-07-28 2005-06-24 Univ Johns Hopkins Med Use of reagents that affect growth differentiation factor-11 (GDF-11) to treat chronic or acute renal disease
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US6992066B2 (en) * 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
ATE325623T1 (de) * 1999-09-14 2006-06-15 Biogen Idec Inc Therapien für chronische niereninsuffizienz unter verwendung von einem oder mehreren integrinantagonist(en)
US20020173453A1 (en) * 2000-12-15 2002-11-21 Rama Akella Method of treating renal injury
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7232802B2 (en) * 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
EP1578360A4 (de) * 2002-08-28 2009-10-21 Curis Inc Gleichzeitige verabreichung von morphogenen und ace-hemmern bei der behandlung von chronischer niereninsuffizienz
WO2005037232A2 (en) 2003-10-17 2005-04-28 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US7844367B2 (en) 2003-12-23 2010-11-30 Rain Bird Corporation Code replacement for irrigation controllers
KR101228233B1 (ko) 2004-03-30 2013-01-31 리립사, 인크. 이온 결합 중합체 및 이의 용도
JP2008500816A (ja) * 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体
US20100150885A1 (en) 2005-06-01 2010-06-17 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US7771995B2 (en) * 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
WO2007056614A1 (en) * 2005-11-14 2007-05-18 Merial Limited Gene therapy for renal failure
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
WO2007087570A2 (en) * 2006-01-24 2007-08-02 Northfield Laboratories, Inc. Polymerized hemoglobin media and its use in isolation and transplantation of islet cells
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
US20090197280A1 (en) * 2006-05-30 2009-08-06 Kristian Bangert Methods and Devices for Rapid Assessment of Severity of Injury
US7722665B2 (en) * 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
US8025881B2 (en) 2006-07-21 2011-09-27 Chugai Seiyaku Kabushiki Kaisha BMP antibodies and methods of treating kidney disease using the same
CA2672560A1 (en) * 2006-12-15 2008-06-26 Ruprecht-Karls-Universitaet Heidelberg Methods for treating podocyte-related disorders
EP2148706A2 (de) * 2007-04-24 2010-02-03 Advanced Technologies and Regenerative Medicine, LLC Gentechnisch hergestelltes nierengewebe
DE102007034580B4 (de) * 2007-07-13 2012-11-08 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Biomaterial basierend auf einem hydrophilen polymeren Träger
US20090155245A1 (en) * 2007-12-18 2009-06-18 Fang Carrie H Treatment for Organ Regeneration with Combination of Drug and Biologics
EP2283119B1 (de) * 2008-05-06 2015-01-07 Joslin Diabetes Center, Inc. Verfahren und zusammensetzungen zur einleitung von brauner adipogenese
JP5485885B2 (ja) * 2008-06-24 2014-05-07 株式会社根本杏林堂 薬液注入装置、この薬液注入装置を有する透視撮像システム、薬液注入装置のコンピュータプログラムおよびデータ処理方法
NZ591437A (en) * 2008-08-28 2013-07-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105021826A (zh) * 2008-08-29 2015-11-04 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN104076152B (zh) * 2008-10-21 2017-04-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN106370857A (zh) * 2008-10-21 2017-02-01 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
NZ592488A (en) 2008-11-10 2012-10-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2009316387B2 (en) * 2008-11-22 2015-01-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010279249B2 (en) 2009-02-06 2015-08-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN106546752A (zh) * 2009-02-06 2017-03-29 阿斯图特医药公司 肾损伤和肾衰竭的诊断及预后
AU2010213591B2 (en) * 2009-02-12 2013-11-21 Stryker Corporation Compositions and methods for minimally-invasive systemic delivery of proteins including TGF-beta superfamily members
EP2396025A2 (de) * 2009-02-12 2011-12-21 Stryker Corporation Periphere verabreichung von proteinen einschliesslich mitglieder der tgf-beta-superfamilie zur systemischen behandlung von störungen und erkrankungen
AU2010223268B2 (en) 2009-03-12 2015-04-23 Haase Investments Gmbh Bone morphogenetic protein 2 (BMP2 ) variants with reduced BMP antagonist sensitivity
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
CA2774024A1 (en) 2009-09-17 2011-03-24 Stryker Corporation Buffers for controlling the ph of bone morphogenetic proteins
MX340078B (es) 2009-11-07 2016-06-24 Astute Medical Inc Metodos y composiciones para el diagnostico y pronostico de daño renal y falla renal.
CN102725636B (zh) 2009-12-20 2015-04-01 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CA2785038A1 (en) 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
CN105158481A (zh) 2010-02-05 2015-12-16 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
US9029093B2 (en) 2010-02-26 2015-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011269847A1 (en) 2010-02-26 2013-01-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
EP2605787B1 (de) 2010-08-20 2017-04-26 Wyeth LLC Osteogene designerproteine
EP3540440B1 (de) 2011-12-08 2022-09-28 Astute Medical, Inc. Verfahren und verwendungen zur bewertung von nierenschäden und nierenstatus
BR112015007749A2 (pt) 2012-10-08 2017-07-04 Relypsa Inc métodos para tratamento de hipertensão , de hipercaliemia , e de doença renal crônica.
EP2925337B1 (de) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutante ngal-proteine und verwendungen davon
CA3158996A1 (en) 2013-01-17 2014-07-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
EP2784083A1 (de) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Knochenmorphogenetische Protein (BMP)-Varianten mit hoch reduzierter Antagonisten-Sensibilität und erweiterter spezifischer biologischer Aktivität
WO2015069998A1 (en) * 2013-11-11 2015-05-14 General Electric Company Method for reducing error in rotor speed measurements
EP2944326B1 (de) 2014-05-16 2018-11-21 Cyanagen Srl Tricarbocyanin-cyclodextrin-konjugate und deren verwendung zur diagnose von nierenkrankheiten
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US11243217B2 (en) 2016-06-06 2022-02-08 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
JP2019528284A (ja) 2016-08-17 2019-10-10 ファクター バイオサイエンス インコーポレイテッド 核酸産物およびその投与方法
JP2019039673A (ja) * 2017-08-22 2019-03-14 セイコーエプソン株式会社 時間デジタル変換回路、回路装置、物理量測定装置、電子機器及び移動体

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) * 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) * 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
DK0429570T3 (da) 1989-03-28 1998-04-27 Genetics Inst Osteoinducerende præparater
EP0536186B1 (de) 1990-05-16 2001-11-21 Genetics Institute, Inc. Knochen- und knorpel-bildung hervorrufende proteine
JPH0426624A (ja) * 1990-05-18 1992-01-29 Tsumura & Co 慢性腎不全改善剤
ATE146076T1 (de) * 1990-06-22 1996-12-15 Du Pont Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
DK0575555T3 (da) 1991-03-11 2001-11-05 Curis Inc Proteininduceret morfogenese
US7056882B2 (en) * 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
CA2116560C (en) 1991-08-30 2002-01-08 Charles M. Cohen Morphogenic protein screening method
EP0601135B1 (de) 1991-08-30 2005-11-02 Curis, Inc. Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
WO1993004692A1 (en) 1991-08-30 1993-03-18 Creative Biomolecules, Inc. Morphogen-induced modulation of inflammatory response
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
KR950702627A (ko) 1992-07-31 1995-07-29 찰스 엠. 코헨 모르포겐 단백질의 가용성 복합체 및 그의 조성물(Morphogenic Protein Soluble Complex and Composition Thereof)
DK0653942T3 (da) 1992-07-31 2003-10-20 Curis Inc Morphogen-induceret nerve-regenerering og -reparation
EP0661933B1 (de) 1992-07-31 1998-04-22 Creative Biomolecules, Inc. Mit morphogen angereicherte nahrungszusammenstellung
JP3973050B2 (ja) 1992-09-16 2007-09-05 キュリス，インコーポレイテッド モルフォゲン誘発性肝再生
EP0672064A1 (de) 1992-11-03 1995-09-20 Creative Biomolecules, Inc. Op 3 - induzierte morphogenese
US5372335A (en) 1992-12-18 1994-12-13 Scott H. Yenzer Aerial marker ball and method of placement
WO1994020539A1 (en) 1993-03-04 1994-09-15 Creative Biomolecules, Inc. Method and compositions for recombinant osteogenic protein production
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
CA2176709A1 (en) * 1993-11-15 1995-05-26 Howard R. Higley Method of treating renal disease by administering igf-i and igfbp-3
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US5723411A (en) * 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
ATE493141T1 (de) * 1996-03-22 2011-01-15 Stryker Corp Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
US5820589A (en) * 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) * 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Also Published As

Publication number Publication date
US20120004171A1 (en) 2012-01-05
US7524817B2 (en) 2009-04-28
US6498142B1 (en) 2002-12-24
CA2254953A1 (en) 1997-11-13
JP2000510835A (ja) 2000-08-22
EP0914146A1 (de) 1999-05-12
JP4766722B2 (ja) 2011-09-07
PT910400E (pt) 2003-12-31
US20100291170A1 (en) 2010-11-18
AU2933997A (en) 1997-11-26
JP2012229268A (ja) 2012-11-22
DE69730966T2 (de) 2006-02-23
ES2203803T3 (es) 2004-04-16
US6861404B1 (en) 2005-03-01
ATE245997T1 (de) 2003-08-15
US8017580B2 (en) 2011-09-13
JP5247593B2 (ja) 2013-07-24
CA2254954A1 (en) 1997-11-13
DE69730966D1 (de) 2004-11-04
ES2230604T3 (es) 2005-05-01
EP0914146B1 (de) 2004-09-29
WO1997041881A1 (en) 1997-11-13
DK0910400T3 (da) 2003-11-24
CA2254953C (en) 2006-09-26
DE69723845T2 (de) 2004-06-03
WO1997041880A1 (en) 1997-11-13
CA2254954C (en) 2010-01-12
DK0914146T3 (da) 2005-01-31
AU2832297A (en) 1997-11-26
US20050143304A1 (en) 2005-06-30
PT914146E (pt) 2005-02-28
DE69723845D1 (de) 2003-09-04
US8377878B2 (en) 2013-02-19
EP0910400A1 (de) 1999-04-28
EP0910400B1 (de) 2003-07-30
JP2009185076A (ja) 2009-08-20
JP2000510124A (ja) 2000-08-08

Similar Documents

Publication Publication Date Title
DE69730966D1 (de) Morphogenische behandlung des chronischen nierenversagens
ATE278414T1 (de) Therapien zur behandlung von akutem nierenversagen
DE60020613D1 (de) (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
ID18729A (id) Sistem penggantian gigi, komponen-komponen untuk sistem penggantian gigi, dan metoda untuk penggantian gigi tersebut
NO970536D0 (no) Behandlingssystem for avgitt blod med skrå reguleringsgrenseflate
DE69432582D1 (de) System zur Administration von Flüssigkeiten bei mehreren Patienten
DE69710095D1 (de) Pharmazeutische zubereitung zur behandlung von diabetes
MXPA02006679A (es) Composicion farmaceutica.
DE69726345D1 (de) Apparat zur extrakorporalen Blutbehandlung
NO972391L (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
ATE226442T1 (de) Anti-chlamydia verfahren und mittel
DE69714451T2 (de) Prionbindende proteine und deren verwendungen
HK1055255A1 (en) Implant comprising immunologically isolated stromal cells and its use
ATE361756T1 (de) Insulinartiger-wachstumsfaktorbindungsprotein-4 protease
DK0972520T3 (da) Frysetörret sammensætning af humant, knoglemorfogenetisk protein MP52
ATE265225T1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
DE29716635U1 (de) Distraktionsvorrichtung zur Behandlung von Knochendefekten
ATE306275T1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten
DE69623112D1 (de) Einheit zur knorpelreparatur
DK0495226T3 (da) Anvendelse af 3-aryl-5-alkylthio-4H-1,2,4-triazoler til behandling af hyperrefleksi som følge af spinaltrauma
DK1214091T3 (da) Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister
FR2764389B1 (fr) Utilisation de venin de crotalus viridis helleri, procede et necessaire pour la determination de la reactivite de la proteine c activee
DE69523250D1 (de) Verwendung von Osteoblast-Proliferationsfaktor
DK0834316T3 (da) Anvendelse af sulbutiamin til behandling af psykomotoriske eller psykointellektuelle problemer
DE69614577D1 (de) Polyamin-antagonisten enthaltende intraokulare irrigationslösung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0914146

Country of ref document: EP

EEIH Change in the person of patent owner